Category: Cardium TherapeuticsSyndicate content

Cardium takes another swing at FDA clearance for wound care product

August 29, 2013 by Sony Salzman

Cardium hands federal regulators all necessary paperwork for a new 510(k) submission of its Excellagen wound care product.

Cardium submits new 510(k) for wound care product

Cardium Therapeutics (NYSE:CXM) appealed to U.S. federal regulators for 510(k) clearance of its Excellagen wound care product after making several modifications and including more specific labeling.

Cardium Therapeutics claims patent win over Boston Scientific

November 21, 2012 by MassDevice staff

Cardium Therapeutics says the European Patent Office hands it a win in a patent war with Boston Scientific over cardiovascular gene therapy technology.

Cardium Therapeutics
Boston Scientific

Bankers' outlook grim for U.S. IPOs | Wall Street Beat

January 5, 2012 by MassDevice staff

Bankers' confidence in U.S. initial public offering growth for 2012 takes a heavy hit, as China tops the international list for largest IPO market in 2011.

Wall Street Beat

Bankers aren't expecting much excitement in the U.S. market for initial public offerings this year, as China spends another year at the top.

About half of the 100 capital markets execs surveyed predict growth in IPOs this year, compared to 72% of those surveyed in advance of 2011, according to BDO USA, an accounting and consulting firm.

Only 16% of those surveyed expected any growth to be "significant," while 35% expect flat growth and 15% predicted that the market will continue to slide.

Zoll shares spike 23 percent on record 2011 sales and earnings | Earnings Roundup

November 17, 2011 by MassDevice staff

Zoll's stock jumped by nearly a quarter overnight after the release of its 2011 earnings report revealing record sales and profits for 2011; plus, Bovie Medical's Q3 profits soar despite sales slide; Cardium Therapeutics pares Q3 losses; Daxor Corp. swings to Q3 loss; Derma Sciences grows Q3 sales, losses; Edap swings to Q3 profits; Fonar Corp.'s Q1 sales, earnings rise; sales plunge as Imris swings to Q3 red; InspireMD's Q3 sales, losses increase; Oridion's Q3 sales, earnings rise; sales down as Patient Safety Technologies swings to Q3 loss; PLC Systems boosts Q3 sales, losses soar; Sanuwave cuts Q3 losses despite lower sales; and Tengion's Q3 losses mount.

Zoll logo

Zoll reported record numbers in its top and bottom line for fiscal year 2011, sending its stock up 23 percent overnight.

Zoll shares were trading at $44.35 in the early afternoon today, up from last night's $35.98 close.

The company's 2011 sales hit a record high of $523.7 million, 18 percent higher than the $444 million posted last year.